Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful. The important notices at the end of this press release should be observed.
Berlin, October 19, 2023 - Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), a leading pan-European company specialising in the production and distribution of medical cannabis, has entered into a partnership with VASCO, a licensed Canadian cannabis producer. This will enable patients in Germany and other European countries to be supplied with high-quality cannabis flowers.
VASCO is bringing premium, indoor cannabis flowers to the market by combining state-of-the-art technology with decades of growing experience. This craft cannabis producer received its cultivation license in 2021 and currently grows plants in just over 2,600 square feet of flowering space and thus focuses on the highest quality and not quantity. The cultivation area is now systematically expanding to over 12,000 square feet, so that the highest demands for premium cannabis flowers continue to be met. By launching VASCO’s strain “White Runtz,” Cantourage is expanding its portfolio in the field of high-quality cannabis products for the European market. VASCO is the tenth cultivation partner that Cantourage will enable to enter the German market in 2023 alone. Highlighting the Berlin-based company's constant commitment to offering patients an unmatched range of diverse products.
Marc Pelletier, Co-Founder of VASCO: “We are constantly asking ourselves how to improve the quality of our work – in terms of our equipment, space design, choice of genetics, or selection of our partners like Cantourage, for example. All of us at VASCO are united by a deep belief in the positive effect of cannabis on health, quality of life, and society as a whole. That’s why we are very excited to partner with Cantourage, which will allow us to bring our products to patients in Europe for the first time.”
Philip Schetter, CEO of Cantourage: “With VASCO, we are now cooperating with another premium production partner. Working with international producers like VASCO, also underscores the strength and appeal of our unique model. This will empower us to sustain future growth and serve an even larger population with top-tier cannabis products via dispensaries."
VASCO is a licensed cannabis producer based in the Bas-Saint-Laurent region of Quebec, Canada, on the banks of the Trois-Pistoles River. The company was founded in 2017 by two brothers with the goal of bringing premium indoor flower to the market. By bundling state-of-the-art technology with decades of on the ground cultivation experience, VASCO combines the know-how of classic cultivation with the efficiencies of the latest technology and techniques. The dedicated team shares a passion for meticulous craftsmanship and takes immense pride in cultivating premium cannabis to meet the needs of all patients.
For further information: www.vascocannabis.com
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.
For further information: www.cantourage.com
This announcement does not constitute a public offer or an advertisement for a public offer for sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
Press contacts at Cantourage:
Klaas Geller | firstname.lastname@example.org | +49.17674717519
Pia Senkel | email@example.com | +49.1733702649